

Yiannis Vasilopoulos

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3912462/publications.pdf>

Version: 2024-02-01

33
papers

1,886
citations

430874

18
h-index

395702

33
g-index

34
all docs

34
docs citations

34
times ranked

2420
citing authors

#	ARTICLE	IF	CITATIONS
1	PARP-1 Expression and BRCA1 Mutations in Breast Cancer Patientsâ€™ CTCs. <i>Cancers</i> , 2022, 14, 1731.	3.7	7
2	Clinical and Genetic Predictors of Glycemic Control and Weight Loss Response to Liraglutide in Patients with Type 2 Diabetes. <i>Journal of Personalized Medicine</i> , 2022, 12, 424.	2.5	10
3	Gene Expression Meta-Analysis of Potential Shared and Unique Pathways between Autoimmune Diseases under Anti-TNF± Therapy. <i>Genes</i> , 2022, 13, 776.	2.4	3
4	Pharmacogenetics of the Glucagon-like Peptide-1 Receptor Agonist Liraglutide: A Step Towards Personalized Type 2 Diabetes Management. <i>Current Pharmaceutical Design</i> , 2021, 27, 1025-1034.	1.9	10
5	Exploring pharmacogenetic variants for predicting response to anti-TNF therapy in autoimmune diseases: a meta-analysis. <i>Pharmacogenomics</i> , 2021, 22, 435-445.	1.3	9
6	Evaluation of 12 GWAS-drawn SNPs as biomarkers of rheumatoid arthritis response to TNF inhibitors. A potential SNP association with response to etanercept. <i>PLoS ONE</i> , 2019, 14, e0213073.	2.5	19
7	Validation study of genetic biomarkers of response to TNF inhibitors in rheumatoid arthritis. <i>PLoS ONE</i> , 2018, 13, e0196793.	2.5	13
8	FCGR3A-V158F polymorphism is a disease-specific pharmacogenetic marker for the treatment of psoriasis with Fc-containing TNF± inhibitors. <i>Pharmacogenomics Journal</i> , 2017, 17, 237-241.	2.0	13
9	Association analysis of FTO gene polymorphisms with obesity in Greek adults. <i>Gene</i> , 2017, 613, 10-13.	2.2	10
10	Netherton Syndrome: A Genotype-Phenotype Review. <i>Molecular Diagnosis and Therapy</i> , 2017, 21, 137-152.	3.8	62
11	Pharmacogenetics and psoriasis: is targeted treatment a possibility?. <i>Pharmacogenomics</i> , 2017, 18, 1627-1630.	1.3	1
12	Replication of PTPRC as genetic biomarker of response to TNF inhibitors in patients with rheumatoid arthritis. <i>Pharmacogenomics Journal</i> , 2016, 16, 137-140.	2.0	31
13	Rheumatoid arthritis response to treatment across IgG1 allotype â€œ anti-TNF incompatibility: a case-only study. <i>Arthritis Research and Therapy</i> , 2015, 17, 63.	3.5	9
14	<i>FCGR</i> polymorphisms in the treatment of rheumatoid arthritis with Fc-containing TNF inhibitors. <i>Pharmacogenomics</i> , 2015, 16, 333-345.	1.3	21
15	A pharmacogenetic study of ABCB1 polymorphisms and cyclosporine treatment response in patients with psoriasis in the Greek population. <i>Pharmacogenomics Journal</i> , 2014, 14, 523-525.	2.0	19
16	Lack of validation of genetic variants associated with antiâ€œtumor necrosis factor therapy response in rheumatoid arthritis: a genome-wide association study replication and meta-analysis. <i>Arthritis Research and Therapy</i> , 2014, 16, R66.	3.5	25
17	Association of FCGR2A with the response to infliximab treatment of patients with rheumatoid arthritis. <i>Pharmacogenetics and Genomics</i> , 2014, 24, 238-245.	1.5	32
18	High serum levels of HIF-1± in psoriatic patients correlate with an over-expression of IL-6. <i>Cytokine</i> , 2013, 62, 38-39.	3.2	28

#	ARTICLE	IF	CITATIONS
19	VDR TaqI is associated with obesity in the Greek population. <i>Gene</i> , 2013, 512, 237-239.	2.2	37
20	Pharmacogenetic Analysis of TNF, TNFRSF1A, and TNFRSF1B Gene Polymorphisms and Prediction of Response to Anti-TNF Therapy in Psoriasis Patients in the Greek Population. <i>Molecular Diagnosis and Therapy</i> , 2012, 16, 29-34.	3.8	72
21	The 3'UTR AACCins5874 in the stratum corneum chymotryptic enzyme gene (SCCE/KLK7), associated with atopic dermatitis; causes an increased mRNA expression without altering its stability. <i>Journal of Dermatological Science</i> , 2011, 61, 131-133.	1.9	21
22	Association Between Polymorphisms in <i>MTHFR</i> and <i>APOA5</i> and Metabolic Syndrome in the Greek Population. <i>Genetic Testing and Molecular Biomarkers</i> , 2011, 15, 613-617.	0.7	19
23	HLA-C, CSTA and DS12346 susceptibility alleles confer over 100-fold increased risk of developing psoriasis: evidence of gene interaction. <i>Journal of Human Genetics</i> , 2011, 56, 423-427.	2.3	13
24	Epidermal Barrier Dysfunction in Atopic Dermatitis. <i>Journal of Investigative Dermatology</i> , 2009, 129, 1892-1908.	0.7	612
25	Skin Barrier Dysfunction in Atopic Dermatitis. <i>Basic and Clinical Dermatology</i> , 2009, , 211-240.	0.1	1
26	Association analysis of the skin barrier gene cystatin A at the PSORS5 locus in psoriatic patients: evidence for interaction between PSORS1 and PSORS5. <i>European Journal of Human Genetics</i> , 2008, 16, 1002-1009.	2.8	27
27	Genetic analysis of autoimmune regulator haplotypes in alopecia areata. <i>Tissue Antigens</i> , 2008, 71, 206-212.	1.0	35
28	The autoimmune regulator gene (<i>AIRE</i>) is strongly associated with vitiligo. <i>British Journal of Dermatology</i> , 2008, 159, ???-???	1.5	54
29	Gene-environment interactions in atopic dermatitis. <i>Drug Discovery Today Disease Mechanisms</i> , 2008, 5, e11-e31.	0.8	2
30	Epidermal barrier dysfunction in atopic dermatitis. <i>Series in Dermatological Treatment</i> , 2008, , 35-58.	0.1	2
31	A nonsynonymous substitution of cystatin A, a cysteine protease inhibitor of house dust mite protease, leads to decreased mRNA stability and shows a significant association with atopic dermatitis. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2007, 62, 514-519.	5.7	56
32	New perspectives on epidermal barrier dysfunction in atopic dermatitis: Gene-environment interactions. <i>Journal of Allergy and Clinical Immunology</i> , 2006, 118, 3-21.	2.9	465
33	Genetic Association Between an AACC Insertion in the 3'UTR of the Stratum Corneum Chymotryptic Enzyme Gene and Atopic Dermatitis. <i>Journal of Investigative Dermatology</i> , 2004, 123, 62-66.	0.7	148